504 results on '"Cho, Eun Yoon"'
Search Results
2. Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response
3. Identification of HER2 ultra-low based on an artificial intelligence (AI)-powered HER2 subcellular quantification from HER2 immunohistochemistry images.
4. Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations
5. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer
6. P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysis
7. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer
8. Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine
9. Author Correction: Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
10. Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients
11. Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer
12. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
13. Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers
14. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway
15. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
16. Supplementary Table 2 from Association of RASSF1A and p63 with Poor Recurrence-Free Survival in Node-Negative Stage I–II Non–Small Cell Lung Cancer
17. Supplementary Table 1 from Association of RASSF1A and p63 with Poor Recurrence-Free Survival in Node-Negative Stage I–II Non–Small Cell Lung Cancer
18. Data from PIK3CA Mutations in In situ and Invasive Breast Carcinomas
19. Supplementary Tables 1-6, Figure 1 from PIK3CA Mutations in In situ and Invasive Breast Carcinomas
20. Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
21. Abstract P2-20-10: Prognostic impact of lymphocyte-Activation Gene-3 (LAG-3) expression in triple negative breast cancer
22. Differences in Prognostic Factors and Failure Patterns Between Invasive Micropapillary Carcinoma and Carcinoma With Micropapillary Component Versus Invasive Ductal Carcinoma of the Breast: Retrospective Multicenter Case–Control Study (KROG 13-06)
23. Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management
24. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems
25. Invasive Paget disease of the breast: 20 years of experience at a single institution
26. Lymphoma Involving Skin and Subcutaneous Fat of the Breast: Two Cases
27. Artificial intelligence (AI)–powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC).
28. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy
29. Detectability and clinicohistological characteristics of small (≤1 cm) invasive breast cancer
30. Are the imaging features of the pleomorphic variant of invasive lobular carcinoma different from classic ILC of the breast?
31. Aberrant DNA methylation of integrin α4 in human breast cancer
32. Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: Matched case–control study
33. A multicenter study of interobserver variability in pathologic diagnosis of papillary breast lesions on core needle biopsy with WHO classification
34. Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
35. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery
36. Synergistic Effect of Bcl-2 and Cyclin A2 on Adverse Recurrence-Free Survival in Stage I Non-small Cell Lung Cancer
37. Expression of TWIST1, Snail, Slug, and NF-κB and methylation of the TWIST1 promoter in mammary phyllodes tumor
38. The prognostic significance of tumor-associated stroma in invasive breast carcinoma
39. Clinicopathologic Risk Factors for the Local Recurrence of Phyllodes Tumors of the Breast
40. Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy?
41. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
42. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
43. Is surgical excision necessary in benign papillary lesions initially diagnosed at core biopsy?
44. Localized tenosynovial giant cell tumor in both knee joints
45. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status
46. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?
47. Does pre-operative breast magnetic resonance imaging in addition to mammography and breast ultrasonography change the operative management of breast carcinoma?
48. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH
49. Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?
50. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.